Fresh analysis indicates that patients who come off new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight much more quickly than those who end traditional lifestyle regimens.
Research printed in a leading health publication shows that while overweight people can lose substantial amounts of their total mass while on the medication, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Users purchasing these drugs should be aware of the risk of rapid weight regain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.
That rate of regain suggests a return to starting mass within about a year and a half.
Comparing Therapies
The study, which looked at 37 of trials involving thousands of participants, contrasted the effects of the injectable medications with older methods.
Researchers note that people who lose weight through lifestyle changes alone usually experience a slower weight regain—approximately 0.1 kg a month—post-intervention.
The Reason for the Fast Regain
Nutrition scientists believe the way of the injections is key to understanding the amplified weight return.
GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations far above than normal may cause the system to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication results in appetite is no longer kept in check, making binge eating a significant risk."
An Ongoing Disease?
Medical guidelines recommend the injections for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals say that, given the high risk of weight regain, the treatment is often ongoing.
This view is reinforced by drug manufacturers, who note that the findings "underscore the long-term character of obesity," akin to managing diseases like diabetes.
Patient Accounts
Users who have discontinued the jabs explain a powerful return of cravings.
"I experienced a trigger that goes on and you're instantly starving," described a patient.
This difficulty is exacerbated if individuals have not established lasting dietary or behavioural changes during treatment.
Widespread Interest
Recent estimates indicate that a significant number of adults in the UK have tried these injections in the past year, with demand continuing to grow.
- Use is more common among females than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Ultimately, clinicians caution that while these medications are potent agents for weight loss, they are not a magic solution and lasting health benefits hinges on ongoing behavioural management.
